Compare RBLX & A Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RBLX | A |
|---|---|---|
| Founded | 2006 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Laboratory Analytical Instruments |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.8B | 39.8B |
| IPO Year | 2020 | 1999 |
| Metric | RBLX | A |
|---|---|---|
| Price | $57.82 | $113.26 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 24 | 16 |
| Target Price | $119.30 | ★ $161.06 |
| AVG Volume (30 Days) | ★ 7.7M | 2.1M |
| Earning Date | 05-04-2026 | 05-27-2026 |
| Dividend Yield | N/A | ★ 0.90% |
| EPS Growth | N/A | ★ 3.16 |
| EPS | N/A | ★ 1.07 |
| Revenue | $2,225,052,000.00 | ★ $4,472,000,000.00 |
| Revenue This Year | $71.62 | $8.42 |
| Revenue Next Year | $18.43 | $6.12 |
| P/E Ratio | ★ N/A | $106.52 |
| Revenue Growth | ★ 15.94 | 6.43 |
| 52 Week Low | $50.10 | $96.43 |
| 52 Week High | $150.59 | $160.27 |
| Indicator | RBLX | A |
|---|---|---|
| Relative Strength Index (RSI) | 37.15 | 30.84 |
| Support Level | N/A | $112.53 |
| Resistance Level | $71.53 | $122.91 |
| Average True Range (ATR) | 3.08 | 3.04 |
| MACD | -0.47 | -0.20 |
| Stochastic Oscillator | 12.63 | 15.29 |
Roblox operates a free-to-play online video game platform with nearly 150 million daily active users. This platform has spawned a virtual universe and a Roblox economy based on the Robux currency. The platform houses millions of games from a wide range of creators—spanning from young gamers themselves to professional development studios. Roblox offers creators the tools, publishing abilities, and platform for their games, enabling anyone to create a game. Creators earn money when gamers make optional in-game purchases within their games and by offering space for real-world advertising, and Roblox earns revenue primarily by taking a cut of these earnings.
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.